Glenmark gave no potential launch date for the generic approved by the FDA at 5 mg and 10 mg strengths. AZ did not mention the impact of generic competition for Farxiga in the US in its full year ...
Farxiga is one of AZ’s most important drugs, and sales increased by 14% to $726 million in the first half of the year, although this was slower than the growth seen in 2018 when sales grew at 30 ...